Analytical Data
-
基因名
APOC2
-
简介
Apolipoprotein C-II Protein, Human (His) is expressed in E. coli with a His tag at the N-terminus. Apolipoprotein C-II Protein, Human (His) has a pharmacological application for the treatment of patients with genetic hypertriglyceridemia caused by ApoC-II otein C-II Protein, Human (His) is expressed in E. coli with 6*His tag at the C-terminus. Apolipoprotein C-II Protein, Human (His) has a pharmacological application for the treatment of patients with genetic hypertriglyceridemia caused by ApoC-II deficiency[1].
- Application
-
别名
rHuApolipoprotein C-II, His; ApoC2; Apolipoprotein C-II
-
种属
Human
-
表达系统
E. coli
-
标签
C-6*His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
P02655
-
表达区间
T23-E101
-
蛋白长度
Full Length of Mature Protein
-
分子量
13 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
APOC2, or apolipoprotein C-II, is a key component in lipid metabolism and plays a critical role in the regulation of triglyceride levels in the bloodstream. It is primarily synthesized in the liver and intestine and is essential for the activation of lipoprotein lipase, an enzyme responsible for the hydrolysis of triglycerides into free fatty acids. Dysregulation of APOC2 has been linked to various metabolic disorders, including hypertriglyceridemia, cardiovascular disease, and pancreatitis. Research on recombinant APOC2 proteins has gained traction in recent years, driven by the need to understand the molecular mechanisms underlying these conditions and to develop targeted therapies. By producing and studying recombinant APOC2, researchers aim to elucidate its role in lipoprotein metabolism, identify potential mutations associated with lipid disorders, and explore its therapeutic potential in the context of lipid-lowering treatments. Moreover, the analysis of recombinant APOC2 can provide insights into its structure-function relationships and interactions with other apolipoproteins and lipid particles, contributing to a more comprehensive understanding of dyslipidemia and its associated risks. The progress in recombinant protein technology has opened new avenues for investigating APOC2, bridging basic research and clinical applications, and ultimately improving patient outcomes in lipid-related diseases.
